CN100339109C - Medicine for treating oligospermatism - Google Patents
Medicine for treating oligospermatism Download PDFInfo
- Publication number
- CN100339109C CN100339109C CNB2004100645296A CN200410064529A CN100339109C CN 100339109 C CN100339109 C CN 100339109C CN B2004100645296 A CNB2004100645296 A CN B2004100645296A CN 200410064529 A CN200410064529 A CN 200410064529A CN 100339109 C CN100339109 C CN 100339109C
- Authority
- CN
- China
- Prior art keywords
- medicine
- treatment
- sperm
- fructus
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses medicine for treating oligospermatism, which comprises 15 to 45 wt% of solomonseal rhizome, 15 to 45 wt% of epimedium, 15 to 45 wt% of desert-living cistanche, 7.5 to 25 wt% of medicinal indianmulberry root, 7.5 to 25 wt% of songaria cynomorium herb, 15 to 45 wt% of tuber fleeceflower root, 7.5 to 25 wt% of pulp of dogwood fruit, 10 to 20 wt% of cassia bark, 7.5 to 25 wt% of south dodder seed, 7.5 to 25 wt% of palmleaf raspberry fruit, 7.5 to 25 wt% of glossy privet fruit, 7.5 to 25 wt% of plantain seed, 7.5 to 25 wt% of malaytea scurfpea fruit, 7.5 to 25 wt% of unprocessed rehmannia root and 7.5 to 25 wt% of phellodendron bark. The medicine of the present invention can effectively increase the quantity and the quality of sperms, can protect the sperms, has obvious curative effects on the oligospermatism, and can simultaneously effectively improve the clinical symptoms of Yin cold, limb cold, sore waist, etc. caused by kidney deficiency.
Description
Technical field
The present invention relates to pharmaceutical product, specifically be applicable to the pharmaceutical composition of treatment oligospermia.
Technical background
Few essence and sperm quality are not high to be the one of the main reasons of male infertility.Human fertility quality has been assisted in the degeneration day by day of mankind spermatozoon quantity and quality directly prestige.Show that after deliberation the deterioration of environment for human survival (such as pollutions such as the chemical contamination in the environment, lonizing radiation pollution, electromagnetic wave, noises) constitutes serious prestige association to the human sperm.People live in this rugged environment for a long time, and the human immune system is easy to suffer damage, so cause the quality and quantity of human endocrine disorder, reproductive system deformity, male sperm to descend, so that had a strong impact on human fertility procreation ability.
Modern medicine thinks, sperm content should be about 0.2-2 be hundred million in every milliliter of 1 ejaculation of normal adult man.If every milliliter＜0.2 hundred million of sperm counts then are called oligospermia.Oligospermia is divided into the special property sent out oligospermia, constitutional oligospermia and Secondary cases oligospermia again.Theory of Chinese medical science thinks that the pathology cause of disease of oligospermia is that natural endowment weakness, menses do not fill, insufficiency of kidney-YANG, can not warm prosperous spermatogenesis or the latent heat of smart chamber, overstrain impairing the spleen, QI and blood decline less, the impairment of YIN consumption is smart.
At present, the specific medicament that does not still have the treatment oligospermia.Clinically, Chloramiphene is the common drug of treatment oligospermia.Chloramiphene is the medicine with weak estrogen activity, it can occupy hypothalamus or (with) estrogen receptor of hypophysis, reduce estrogenic negative feedback, promote the release of glandular hormone, strengthen testicular spermatogenic function.If this drug main is at spy's property the sent out oligospermia that causes because of the promoting sexual gland hormone shortage, so clinical application range is narrow.In addition, this medicine is artificial synthetic chemicals, and period in a medicine usually untoward reaction such as depression, giddy, blurred vision, allergy can occur, also can cause hepatic injury when serious.
Summary of the invention
Purpose of the present invention just provides a kind of medicine that is suitable for treating oligospermia, especially is suitable for improving the medicine of sperm quantity and quality.
The present invention is made by the following weight proportion raw material:
Rhizoma Polygonati 15-45 part, Herba Epimedii 15-45 part, Herba Cistanches 15-45 part, Radix Morindae Officinalis 7.5-25 part, Herba Cynomorii 7.5-25 part, Radix Polygoni Multiflori 15-45 part, Fructus Corni 7.5-25 part, Cortex Cinnamomi 10-20 Fen, Semen Cuscutae 7.5-25 part, Fructus Rubi 7.5-25 part, Fructus Ligustri Lucidi 7.5-25 part, Semen Plantaginis 7.5-25 part, Fructus Psoraleae 7.5-25 part, Radix Rehmanniae 7.5-25 part, Cortex Phellodendri 7.5-25 part.
Preferred version of the present invention is to select for use the following weight proportion raw material to make:
Rhizoma Polygonati 30-40 part, Herba Epimedii 30-40 part, Herba Cistanches 30-40 part, Radix Morindae Officinalis 15-20 part, Herba Cynomorii 15-20 part, Radix Polygoni Multiflori 15-20 part, Fructus Corni 15-20 part, Cortex Cinnamomi 10-15 Fen, Semen Cuscutae 15-20 part, Fructus Rubi 15-20 part, Fructus Ligustri Lucidi 15-20 part, Semen Plantaginis 15-20 part, Fructus Psoraleae 15-20 part, Radix Rehmanniae 15-20 part, Cortex Phellodendri 15-20 part.
The present invention mainly is the deficiency of kidney-QI at oligospermia, and deficiency-fire produced in the interior, the seminal fluid of burning carry out prescription.The present invention selects for use Rhizoma Polygonati, Herba Epimedii with the kidney invigorating and essence nourishing, regulates male's organism endocrine, to reach the purpose of spermatogenesis, monarch drug in its side of being; Select Herba Cistanches, Radix Morindae Officinalis, Herba Cynomorii, Radix Polygoni Multiflori, Fructus Corni, Cortex Cinnamomi warming the kidney to activate YANG, benefit essence for use, ministerial drug in its side of being; Xuan Yong Semen Cuscutae, Fructus Rubi, Fructus Ligustri Lucidi, Semen Plantaginis, Fructus Psoraleae controlling nocturnal emission with astringent drugs QI invigorating, the benefit of promoting the production of body fluid essence, soothing the liver are adjuvant drug in the side; Select Radix Rehmanniae, Cortex Phellodendri for use, grow sun, digestion stagnant heat, draw messenger drug in the through disease side of doing of all medicines.
Medicine of the present invention can be prepared into oral formulations such as oral liquid, the watered pill, honeyed pill, capsule, tablet.Preparation method can adopt that conventional method is prepared in the pharmaceutical preparation.
The present invention provides a kind of preparation method of the watered pill as follows at this:
Take by weighing crude drug of the present invention, clean respectively, dry below 60 ℃, pulverize, behind mistake 100 mesh sieves, mix homogeneously.Mixed medicated powder is added an amount of distillation hydration again and stick together, put into the little watered pill that pellet processing machine is made the 100--120mg/ ball, drying is finished product.
The usage and dosage of watered pill of the present invention is: oral, and each 40-50 ball.One twice-daily or follow the doctor's advice.Common three months is a course of treatment.As when making oral liquid, tablet or capsule, can be with reference to the taking dose of the watered pill.
Should avoid pungent and tobacco and wine during taking medicine of the present invention.
Medicine of the present invention has the kidney invigorating and essence nourishing, digestion stagnant heat, promotes testicular spermatogenic and cytocerastic effect, can significantly improve sperm quantity and sperm survival rate and motility of sperm.
Medicine of the present invention can be used for treating oligospermia, is particularly suitable for because of few essence, azoospermia or the not good enough male infertility that causes of sperm quality.Medicine of the present invention also can be used for treating diseases such as impotence and premature ejaculation, the soreness of waist are weak, dizziness and tinnitus.
Beneficial effect of the present invention has obtained confirmation by following experiment:
Experimental technique:
Case is selected: selecting the oligospermia patient is experimental subject of the present invention.
Oligospermia patient's diagnostic criteria is published according to the People's Health Publisher, " human seminal fluid and sperm-cervical mucus interaction laboratory inspection handbook (1984:24) formulation that World Health Organization (WHO) writes, promptly sterile more than 2 years, repeatedly seminal fluid routine test sperm concentration is lower than 20 * 10
9/ L.
Selected 168 routine oligospermia patients are the special outpatient clinic patient, are divided into two groups at random, and 138 examples are organized in treatment, matched group 30 examples.Treatment group age 22-38 year, average (28.6 ± 3.2) year; Marriageable age 2-12, average 3.5 years.Matched group age 23-36 year, average (28.5 ± 3.4) year; Marriageable age 2-11, average 3.6 years.Two groups of physical data compare no significant difference (P＞0.05), have comparability.
Experimental technique: treatment group patient takes the watered pill of medicine of the present invention, each 40 balls, and every day 2 times, serveing on 3 months is a course of treatment.The matched group patient takes Chloramiphene, and each 25mg is once a day, oral; Serve on 25, drug withdrawal 5 days, serveing on 3 months is a course of treatment.
Curative effect determinate standard: take a course of treatment, treatment back wife's patient pregnancy or sperm concentration surpass 20 * 10
9/ L, the normal person of vigor is for curing; The more preceding increase by 10 * 10 of treatment back patient's sperm count
9/ L is above to be produce effects; The more preceding increase by 1 * 10 of treatment back patient's sperm count
9/ L is effective; Patient's sperm count no change in treatment back is invalid.
Statistical method: ranked data adopt rank test, and (X ± S) expression relatively adopts paired t-test before and after the group internal therapy to measurement data with mean ± standard deviation.
Experimental result is as follows:
Clinical symptoms change (seeing Table 1).
Cardinal symptom changes before and after the table 1 liang group treatment
| Symptom | Treatment group (n=138) | Effective percentage % | Matched group (n=30) | Effective percentage % | ||||||
| n | Disappear | Take a turn for the better | No change | n | Disappear | Take a turn for the better | No change | |||
| The smart tired power of YIN-cold cold extremities soreness of the waist and knees | 102 113 112 | 52 58 29 | 49 53 62 | 1 2 1 | 99.02 98.23 99.11 | 27 25 28 | 9 7 8 | 12 10 14 | 6 8 6 | 77.78 68.00 78.57 |
Improve the symptom total effective rate, treatment group 98.59%, matched group 75.0%.Two groups are compared P＜0.01.
The routine of seminal fluid changes (seeing Table 2).
The routine of table 2 liang group seminal fluid becomes x ± s
| Treatment group (n=138) | Matched group (n=30) | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Survival rate (%) sperm concentration leukocyte count is (individual/HP) rate of teratosperm (%) | 27.39±0.12 5.05±0.11 10±2 21.6±5.1 | 35.72±0.25△ 49.12±0.78△ 2±1△ 14.3±3.2△ | 27.46±0.15 5.12±0.11 10±3 21.8±5.2 | 35.68±0.23▲ 12.84±0.68▲ 9±2 20.1±3.1 |
Annotate: relatively, △ is P＜0.05, P＜0.01 ▲ be before and after the treatment
By table 2 as seen, the present invention has the effect of tangible raising sperm quantity.After two groups of treatments the survival rate of sperm and sperm concentration are obviously increased, but the present invention also can make the abnormal rate of sperm and the quantity of leucocyte of seminal fluid obviously descend, and matched group can not improve the abnormal rate of sperm and the quantity of leucocyte in the seminal fluid.
The mobility of sperm changes (seeing Table 3)
Table 3 a liang group sperm motility degree changes x ± s
| Treatment group (n=138) | Matched group (n=30) | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Gun is the rectilinear motion inertia of not advancing at a slow speed | 11.4±0.5 13.1±0.2 14.6±0.3 66.6±0.6 | 15.7±0.4▲ 13.6±0.4 9.1±0.4▲ 62.5±0.7 | 11.5±0.6 13.4±0.3 14.6±0.5 65.8±0.8 | 14.2±0.5▲ 13.8±0.5 12.6±0.6 65.7±0.8 |
Compare before and after the treatment, ▲ be P＜0.05
By table 3 as seen, the two groups of mobilities that all can obviously improve sperm especially increase the gun of sperm, with the treatment before notable difference (P＜0.05) is relatively arranged.In addition, the present invention can also make not progressive sperm quantity reduce, and the matched group contrast is not obvious.
The variation of gonadal hormone (seeing Table 4).
The level of table 4 liang group patient gonadal hormone changes
| Treatment group (n=138) | Matched group (n=30) | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Follicule-stimulating hormone (FSH) (FSH) U/L lutropin (LH) U/L prolactin antagonist (PRL) mmoI/L estradiol (E 2) mmoI/L progesterone (P) mmoI/L testosterone (T) mmoI/L | 14.52±0.6 19.36±0.8 1.04±0.08 163.65±20.55 2.27±0.21 10.09±0.54 | 12.21±0.5▲ 22.98±1.2▲ 0.58±0.03▲ 221.01±21.65▲ 5.57±0.40▲ 10.10±0.58▲ | 14.32±0.7 19.10±0.6 1.050±0.10 166.29±21.29 2.24±0.21 9.98±0.54 | 12.98±0.8▲ 22.53±1.4▲ 0.61±0.04▲ 218.92±21.65▲ 5.26±0.38▲ 18.42±0.58▲ |
Compare ▲ P＜0.05 before and after the treatment
By table 4 as seen, two groups of treatment backs are similar to the influence of gonadal hormone, descend as serum FSH, PRL level, and LH, E2, P, T level all have rising in various degree, with more all there were significant differences (P＜0.05) before the treatment.
Two groups of curative effects compare (seeing Table 5):
Table 5 liang group curative effect relatively
| Group | n | Produce effects | Effectively | Invalid | Effective percentage |
| Treatment group matched group | 138 30 | 65 7 | 69 12 | 4 11 | 97.10▲ 65.33 |
Compare with matched group, ▲ be P＜0.05
This shows that the present invention has significant curative effect to the treatment oligospermia.
Animal experiment study
Experiment medicine: medicine watered pill of the present invention.
Animal: 40 of SD rats, body weight 200g-250g all is male, is provided by Hebei province's Experimental Animal Center.
Experimental technique:
40 rats are divided into 10 of blank groups, 10 of positive controls, 20 of experimental grouies.Wherein the blank group is fed normal feedstuff, every day about 10g/200g body weight, 35ml water; Positive controls is fed with the feedstuff (being formulated in the feedstuff by the calculating of 20mg/kg/ day gossypol acetate) of gossypol acetate; Experimental group is fed with the feedstuff of gossypol acetate and medicine watered pill of the present invention, and (content of gossypol acetate is identical with positive controls in the feedstuff, and other adds medicine watered pill 0.2g/kg/ day of the present invention (according to the conversion of the clinical consumption of adult).Divide morning and evening twice feed material and water every day, wherein feed normal feedstuff 8g morning, feed experiment feedstuff 7g evening.Claim body weight weekly one time, and by body weight increase and decrease day hello experiment forage volume.After three months, put to death animal with the anesthesia of 1% sodium pentobarbital.Testis is weighed, and (method of counting is pressed " shanghai Medicine " 1996,10 (4) to the homogenate counting: 214-216) described method).
Observation index and method:
Carry out testis, the analysis of epididymis weight coefficient; Carry out sperm count, the analysis of sperm motility degree; Carry out sperm morphology, quantity and pathology section examination thereof; Date processing adopts the t check.
Experimental result sees Table 6, table 7, Fig. 1, Fig. 2, Fig. 3, Fig. 4, Fig. 5, Fig. 6.
Description of drawings:
Fig. 1 is the pathological section figure of blank group;
Fig. 2 is the pathological section figure of positive controls;
Fig. 3 is the pathological section figure of experimental group;
Fig. 4 is the sperm morphology and the number figure of blank group;
Fig. 5 is the sperm morphology and the number figure of positive controls;
Fig. 6 is the sperm morphology and the number figure of experimental group;
Rat body weight, testis and epididymis weight coefficient change (seeing Table 6)
Table 6 rat is respectively organized body weight, testis and the epididymis weight coefficient changes (x ± s)
| Group | Body weight (g) | Testis/body weight (%) | Epididymis body weight (%) |
| Blank group (n=9) positive controls (n=8) experimental group (n=15) | 535±40.6 516.5±33.1 513.3±40.3 | 0.30±40.6 0.30±0.09 0.37±0.04 | 0.055±0.010 0.053±0.012 0.06±0.010 |
Relatively positive controls, experimental group are light than the blank group from numerical value, but respectively organize equal not statistically significant.
Rat spermatozoa counting and sperm motility be (seeing Table 7) relatively
Table 7 is respectively organized relatively (X ± SD) of sperm count and sperm motility
| Group | Sperm count (1,000,000 10ml) | Sperm motility degree (%) |
| Blank group (n=9) positive controls (n=8) experimental group (n=15) | 437.2±121.8 291.3±68.1△ 416±41.5▲ | 90±63 26±15△ 56±29▲ |
Annotate: positive controls and blank group comparison △ are P＜0.01; Experimental group and blank group compare ▲ are P＜0.05;
Can find out that the convoluted seminiferous tubule of positive controls rat has slight damage from the pathological section contrast of Fig. 1, Fig. 2, Fig. 3, gauffer is misaligned. The convoluted seminiferous tubule not damaged of experimental group rat.
From Fig. 5, Fig. 6, Fig. 7 (utilizing the Wright's staining body to observe sperm morphology and number) relatively can find out that experimental group is compared with the blank group, form indistinction, and number is more. And positive controls is compared with the blank group, and form is relatively poor, and number has obvious minimizing.
From above-mentioned zoopery, can find out; Dichlorodiphenyl Acetate gossypol of the present invention causes the diseases such as male adult rat convoluted seminiferous tubule damage, oligozoospermia to have obvious protection and rises smart effect (P＜0.05), and sperm motility also has obvious raising (P＜0.05) simultaneously. This Experiment and clinic presentations experimental result is basic identical.
Medicine of the present invention shows that through acute toxicity, long term toxicity test toxic and side effect is not found in clinical use yet without obvious toxicity.
In sum; but the quality and quantity of medicine Effective Raise sperm of the present invention also has protective effect to sperm; aspermia or oligospermia is had significant result for the treatment of, also can effectively improve simultaneously the clinical symptoms such as the cold sensation of the genitalia limb that causes because suffering from a deficiency of the kidney is cold, soreness and weakness of waist and knees, smart tired power.
The specific embodiment
Embodiment 1 watered pill preparation
Take by weighing Rhizoma Polygonati 30kg, Herba Epimedii 30kg, Herba Cistanches 30kg, Radix Morindae Officinalis 15kg, Herba Cynomorii kg, Radix Polygoni Multiflori 15kg, Fructus Corni 15kg, Cortex Cinnamomi 10kg, Semen Cuscutae 15kg, Fructus Rubi 15kg, Fructus Ligustri Lucidi 15kg, Semen Plantaginis 15kg, Fructus Psoraleae 15-20 part, Radix Rehmanniae 15-20 part, Cortex Phellodendri 15-20 part.
The above-mentioned raw materials medicine is cleaned respectively, dry below 60 ℃, pulverize, behind mistake 100 mesh sieves, mix homogeneously.Again mixed medicated powder is added an amount of distillation hydration and sticks together, put into the little watered pill that pellet processing machine is made the 120mg/ ball, be sprinkled into an amount of Pulvis Talci polishing uniformly then, after inserted 60 ℃ of dryings of far infrared electric oven 4 hours, remove moisture content, be finished product.
Embodiment 2 capsule preparations
Take by weighing Rhizoma Polygonati 40kg, Herba Epimedii 40kg, Herba Cistanches 40kg, Radix Morindae Officinalis 20kg, Herba Cynomorii 20kg, Radix Polygoni Multiflori 20kg, Fructus Corni 20kg, Cortex Cinnamomi 15kg, Semen Cuscutae 20kg, Fructus Rubi 20kg, Fructus Ligustri Lucidi 20kg, Semen Plantaginis 20kg, Fructus Psoraleae 20kg, Radix Rehmanniae 20kg, Cortex Phellodendri 15-20kg; The above-mentioned raw materials medicine is cleaned respectively, dry below 60 ℃, pulverize, behind mistake 100 mesh sieves, in incapsulating behind the mix homogeneously, the 500mg/ grain.
The preparation method of embodiment 3,4 is identical with embodiment 1, and the preparation method of embodiment 5,6,7 is identical with embodiment 2, is that raw materials used proportional quantity is different, but all can reaches effect of the present invention.
Claims (2)
1, a kind of medicine that is used for the treatment of oligospermia is characterized in that it is made by the following weight proportion raw material:
Rhizoma Polygonati 15-45 part, Herba Epimedii 15-45 part, Herba Cistanches 15-45 part, Radix Morindae Officinalis 7.5-25 part, Herba Cynomorii 7.5-25 part, Radix Polygoni Multiflori 15-45 part, Fructus Corni 7.5-25 part, Cortex Cinnamomi 10-20 Fen, Semen Cuscutae 7.5-25 part, Fructus Rubi 7.5-25 part, Fructus Ligustri Lucidi 7.5-25 part, Semen Plantaginis 7.5-25 part, Fructus Psoraleae 7.5-25 part, Radix Rehmanniae 7.5-25 part, Cortex Phellodendri 7.5-25 part.
2, the medicine that is used for the treatment of oligospermia according to claim 1 is characterized in that it is made by the following weight proportion raw material:
Rhizoma Polygonati 30-40 part, Herba Epimedii 30-40 part, Herba Cistanches 30-40 part, Radix Morindae Officinalis 15-20 part, Herba Cynomorii 15-20 part, Radix Polygoni Multiflori 15-20 part, Fructus Corni 15-20 part, Cortex Cinnamomi 10-15 Fen, Semen Cuscutae 15-20 part, Fructus Rubi 15-20 part, Fructus Ligustri Lucidi 15-20 part, Semen Plantaginis 15-20 part, Fructus Psoraleae 15-20 part, Radix Rehmanniae 15-20 part, Cortex Phellodendri 15-20 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100645296A CN100339109C (en) | 2004-11-08 | 2004-11-08 | Medicine for treating oligospermatism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100645296A CN100339109C (en) | 2004-11-08 | 2004-11-08 | Medicine for treating oligospermatism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772192A CN1772192A (en) | 2006-05-17 |
| CN100339109C true CN100339109C (en) | 2007-09-26 |
Family
ID=36759444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100645296A Expired - Fee Related CN100339109C (en) | 2004-11-08 | 2004-11-08 | Medicine for treating oligospermatism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100339109C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101376010B (en) * | 2008-09-27 | 2010-11-10 | 曹开镛 | Vigor formulation for producing sperm for treating asthenospermia and preparation method thereof |
| CN103860889A (en) * | 2012-12-09 | 2014-06-18 | 邓小立 | Traditional Chinese medicine for treating oligospermia and asthenozoospermia |
| CN103908574B (en) * | 2014-04-12 | 2017-10-17 | 福建中合医药股份有限公司 | Pharmaceutical composition with the strong essence effect of kidney tonifying and preparation method thereof |
| CN113209224A (en) * | 2021-06-08 | 2021-08-06 | 河北科技大学 | External composition for enhancing male functions and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095603A (en) * | 1993-05-21 | 1994-11-30 | 陈居玫 | The manufacture method of male goat " Sanbian " nutitious liquor |
| CN1105878A (en) * | 1994-10-22 | 1995-08-02 | 中外合作中国广西梧州瑞福祥药业有限公司 | China "Meng'nan" capsule-treating man sex function disturbance |
| CN1182127A (en) * | 1997-09-01 | 1998-05-20 | 黄志光 | Medicated wine capable of invigorating life essence and vital energy and tranquilizing |
| CN1298736A (en) * | 1999-12-30 | 2001-06-13 | 湘潭市科林皮肤病慢性病研究所 | Medicine for treating man's sterility |
| CN1401373A (en) * | 2002-09-19 | 2003-03-12 | 朱翻身 | Chinese medicine for treating male sexual disfunction and preparing process thereof |
-
2004
- 2004-11-08 CN CNB2004100645296A patent/CN100339109C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095603A (en) * | 1993-05-21 | 1994-11-30 | 陈居玫 | The manufacture method of male goat " Sanbian " nutitious liquor |
| CN1105878A (en) * | 1994-10-22 | 1995-08-02 | 中外合作中国广西梧州瑞福祥药业有限公司 | China "Meng'nan" capsule-treating man sex function disturbance |
| CN1182127A (en) * | 1997-09-01 | 1998-05-20 | 黄志光 | Medicated wine capable of invigorating life essence and vital energy and tranquilizing |
| CN1298736A (en) * | 1999-12-30 | 2001-06-13 | 湘潭市科林皮肤病慢性病研究所 | Medicine for treating man's sterility |
| CN1401373A (en) * | 2002-09-19 | 2003-03-12 | 朱翻身 | Chinese medicine for treating male sexual disfunction and preparing process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1772192A (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1061854C (en) | Medicinal preparation for treatment and prevention of gynopathy | |
| CN1092981C (en) | Medicine for curing arthralgia-syndrome resulted from wind,cold and dampness and its preparation method | |
| CN100339109C (en) | Medicine for treating oligospermatism | |
| CN1259955C (en) | Chinese medicine preparation for treating climacteric metancholia of women | |
| CN1931280A (en) | Medicine for treating osteoporosis and its prepn process | |
| CN1250264C (en) | Capsule for curing hyperplasia of mammary glands and its preparation method | |
| CN108186852B (en) | Medicinal composition for preventing and treating femoral head necrosis and preparation method thereof | |
| CN102441111A (en) | Chinese patent medicine used for treating infertility, and preparation method thereof | |
| CN115837065A (en) | Traditional Chinese medicine composition and application thereof | |
| CN102284037B (en) | Medicament for treating involutional melancholia | |
| CN1228076C (en) | Chinese drugs for treating preceded menstrual cycle and excessive menses due to blood heat | |
| CN1199679C (en) | Medicine for nourishing yin and fortifying kidney, benefiting qi and fortifying spleen , and its preparation method | |
| CN1401373A (en) | Chinese medicine for treating male sexual disfunction and preparing process thereof | |
| CN1176794A (en) | Medicine for treating masculine sterility | |
| CN112451608A (en) | Kidney-tonifying yang-warming collateral-dredging formula with bone and kidney simultaneous treatment effect | |
| CN102205031B (en) | Traditional Chinese medicine for treating male sterility | |
| CN1772239A (en) | Chinese medicine prepn for treating vaginitis and cervicitis | |
| CN113144103B (en) | Traditional Chinese medicine composition for clearing throat and application thereof | |
| CN103385953B (en) | A traditional Chinese medicine composition for the treatment of menopausal uterine fibroids and applications thereof | |
| CN1052414C (en) | Prescription of chun wine and preparation technology thereof | |
| CN102357179B (en) | Medicine for treating antisperm antibody induced infertility or habitual abortion and preparation method thereof | |
| CN105963589A (en) | Traditional Chinese medicine for treating sperm abnormality | |
| CN1263490C (en) | Yang reinforcing medicine and its preparation method | |
| CN101361955B (en) | Traditional Chinese medicine combination for treating rheumatism | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070926 Termination date: 20111108 |